[1] Seo BM, Miura M, Gronthos S, et al. Investigation of multipotent postnatal stem cells from human periodontal ligament [J]. Lancet, 2004, 364(9429): 149-155. [2] Ming L, Jin F, Huang P, et al. Licochalcone A up-regulates of FasL in mesenchymal stem cells to strengthen bone formation and increase bone mass [J]. Sci Rep, 2014, 4: 7209. [3] Gemmell E, Yamazaki K, Seymour GJ. The role of T cells in periodontal disease: homeostasis and autoimmunity [J]. Periodontol 2000, 2007, 43: 14-40. [4] Wang HL, Greenwell H, Fiorellini J, et al. Periodontal regeneration [J]. J Periodontol, 2005, 76(9): 1601-1622. [5] Yamada Y, Fujimoto A, Ito A, et al. Cluster analysis and gene expression profiles: a cDNA microarray system-based comparison between human dental pulp stem cells (hDPSCs) and human mesenchymal stem cells (hMSCs) for tissue engineering cell therapy [J]. Biomaterials, 2006, 27(20): 3766-3781. [6] Liu Y, Zheng Y, Ding G, et al. Periodontal ligament stem cell-mediated treatment for periodontitis in miniature swine [J]. Stem Cells, 2008, 26(4): 1065-1073. [7] Kong X, Liu Y, Ye R, et al. GSK3beta is a checkpoint for TNF-alpha-mediated impaired osteogenic differentiation of mesenchymal stem cells in inflammatory microenvironments [J]. Biochim Biophys Acta, 2013, 1830(11):5119-5129. [8] Huang GT, Gronthos S, Shi S. Mesenchymal stem cells derived from dental tissues vs. those from other sources: their biology and role in regenerative medicine [J]. J Dent Res, 2009, 88(9): 792-806. [9] Akiyama K, Chen C, Wang D, et al. Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis [J]. Cell Stem Cell, 2012, 10(5): 544-555. [10] Brunner T, Wasem C, Torgler R, et al. Fas (CD95/Apo-1) ligand regulation in T cell homeostasis, cell-mediated cytotoxicity and immune pathology [J]. Semin Immunol, 2003, 15(3):167-176. [11] Steiert AE, Sendler D. Burke WF, et al. Attack the tumor counterattack-c-FLIP expression in Jurkat-T-cells protects against apoptosis induced by coculture with SW620 colorectal adenocarcinoma cells [J]. J Surg Res, 2012, 176(1):133-140. [12] Rippo MR, Babini L, Prattichizzo F, et al. Low FasL levels promote proliferation of human bone marrow-derived mesenchymal stem cells, higher levels inhibit their differentiation into adipocytes [J]. Cell Death Dis, 2013, 4: e594. [13] Garcia AJ, Tom C, Guemes M, et al. ERalpha signaling regulates MMP3 expression to induce FasL cleavage and osteoclast apoptosis [J]. J Bone Miner Res, 2013, 28(2):283-290. [14] Shao B, Liao L, Yu Y, et al. Estrogen preserves Fas ligand levels by inhibiting microRNA-181a in bone marrow-derived mesenchymal stem cells to maintain bone remodeling balance [J]. FASEB J, 2015, 29(9):3935-3944. [15] Shao B, Fu X, Yu Y, et al. Regulatory effects of miRNA181a on FasL expression in bone marrow mesenchymal stem cells and its effect on CD4+T lymphocyte apoptosis in estrogen deficiencyinduced osteoporosis [J]. Mol Med Rep, 2018, 18(1): 920-930. [16] Svandova E, Vesela B, Lesot H, et al. FasL modulates expression of Mmp2 in osteoblasts [J]. Front Physiol, 2018, 9: 1314. |